Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: EXCRETION Clear all
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

NCT03316131
View directory record Official record
Conditions
Asymptomatic Hyperuricemia
Interventions
Verinurad, Febuxostat, Dapagliflozin, Dapagliflozin matched placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects

NCT01442831
View directory record Official record
Conditions
Healthy
Interventions
Human ADME
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants

NCT04023877
View directory record Official record
Conditions
Dementias With Lewy Bodies
Interventions
E2027
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 19, 2026, 2:01 PM EDT
Not listed No phase listed Observational

Electronic Mobile Phone App Stool Diary

NCT04644133
View directory record Official record
Conditions
Constipation, Incontinence Bowel
Interventions
Paper diary, Electronic APP diary
Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
135 participants
Timeline
2018 – 2024
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Phase 2Phase 3 Interventional Results available

SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study

NCT02778867
View directory record Official record
Conditions
Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis (EoE)
Interventions
1 Food Elimination Diet Therapy, 6 Food Elimination Diet Therapy, 6 Food Elimination Diet (after 1FED failure), Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
Other · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 60 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AME Study of [14C]-YH4808 in Healthy Male Subjects

NCT01825707
View directory record Official record
Conditions
Healthy
Interventions
[14C]-YH4808 200 mg
Drug
Lead sponsor
Yuhan Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 19, 2026, 2:01 PM EDT
Recruiting Not applicable Interventional

Applause Study I - Append System Early Feasibility Study

NCT07278869
View directory record Official record
Conditions
Non Valvular Atrial Fibrillation
Interventions
Left Atrial Appendage Elimination: Append System
Device
Lead sponsor
Append Medical Ltd.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Jonesboro, Arkansas • Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Phase 1 Interventional

Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

NCT00478725
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
GW786034, oral, GW786034, IV, GW786034, radiolabeled oral
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion

NCT01059474
View directory record Official record
Conditions
Toxicity
Interventions
transdermal DMPS
Drug
Lead sponsor
Banner Health
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants

NCT06180954
View directory record Official record
Conditions
Healthy
Interventions
[14C]-LOXO-305, LOXO-305
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 19, 2026, 2:01 PM EDT
Not listed Not applicable Interventional

Efficacy of (WaterWorks®)Douching Device for Elimination of Perceived Vaginal Odor Not Caused by BV or Vaginitis

NCT00417365
View directory record Official record
Conditions
Vaginal Odor
Interventions
WaterWorks Douching Device
Device
Lead sponsor
Abbott Research Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Aventura, Florida • Plantation, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2007 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Mass Balance Study

NCT00828763
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14c}-GSK1349572
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 5, 2009 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184

NCT01824446
View directory record Official record
Conditions
Healthy
Interventions
Radiolabeled SPD602 (FBS0701, SSP-004184)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 19, 2026, 2:01 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma

NCT07660731
View directory record Official record
Conditions
Healthy Volunteer Study, Healthy Adults, Healthy Participants, Asthma
Interventions
PF-08103402, Placebo, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 2:01 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Randomized Study Of Novel Enuresis Alarm vs Standard Bedwetting Alarm

NCT05214131
View directory record Official record
Conditions
Bedwetting, Nocturnal Enuresis, Urinary Incontinence
Interventions
gogoband, SNEA group
Device
Lead sponsor
Yale University
Other
Eligibility
6 Years to 21 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 19, 2026, 2:01 PM EDT
Not listed Not applicable Interventional

Enuresis Alarm - Is a Manual Trigger System Beneficial?

NCT03522818
View directory record Official record
Conditions
Enuresis, Nocturnal
Interventions
Manual Trigger, Normal
Behavioral
Lead sponsor
Gina Lockwood
Other
Eligibility
5 Years to 15 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 19, 2026, 2:01 PM EDT
Not yet recruiting Phase 3 Interventional

RB-PDT for Fusarium Keratitis: The LUMIERE Study

NCT07743489
View directory record Official record
Conditions
Fusarium Keratitis
Interventions
Rose Bengal Photodynamic Therapy, Sham RB-PDT
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Palo Alto, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Oral Probiotics and Herbal Supplementation on the Gut Microbiome and Sebum Excretion Rate in Non-Cystic Acne

NCT05919810
View directory record Official record
Conditions
Acne Vulgaris, Acneiform Eruptions, Skin Diseases, Sebaceous Gland Diseases
Interventions
Probiotic, Oral herbal powder supplement
Other · Dietary Supplement
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
12 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers

NCT00501683
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
Radiolabelled GSK189075
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 19, 2026, 2:01 PM EDT
Recruiting Phase 1 Interventional

Excretion of Rivaroxaban in Human Breast Milk

NCT06831474
View directory record Official record
Conditions
Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism), Rivaroxaban, Breastfeeding, Breast Milk Collection
Interventions
Rivaroxaban 10 MG Oral Tablet, Rivaroxaban 20 MG Oral Tablet
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects

NCT04018950
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infections
Interventions
ETX2514, 14C-ETX2514
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 19, 2026, 2:01 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

NCT01273103
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
200mg [14C]- GSK2248761
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
30 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379

NCT07712718
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-MRM-3379
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Results available

Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus

NCT00502242
View directory record Official record
Conditions
Kidney Transplant
Interventions
ramipril
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
24
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Oct 19, 2026, 2:01 PM EDT